Secreted N-pyroglutamyl/C-amide Peptide Library

	Catalog #	Size	Price
	L-018	109 peptides	$5873

Protocol:	View/Download (PDF) - for reference only
Storage:	96 well plate(s), where each well contains 1.5 nmol of peptide packaged in 15µg of BSA. (Please inquire for larger peptide quantity). Individual peptide quotations please email [email protected]
MSDS:	View/Download(PDF)

	Peptide Name	Catalog No.	M.W.
Plate I
1	TAC4 gamma (47-61)-amide(Human)	046-97	1652.9
2	CAP-LAMB2 (Mouse)	050-25	509.2
3	CAP-ADAMTS18 (Mouse)	050-27	799.94
4	CAP-VIP1 (Mouse)	050-64	1374
5	CAP-TAC1 (Human, Mouse)	061-40	723.3
6	CAP-OBSCN (Mouse)	050-29	570.3
7	CAP-FGF5 (Human, Mouse)	050-30	585.3
8	CAP-EMILIN1 (Mouse)	050-31	369.2
9	CAP-WNT3A (Mouse)	050-33	431.2
10	CAP-THBS4 (Mouse)	050-35	427.2
11	CAP-CSF1 (Mouse)	050-73	2210
12	CAP-COL27A1 (Human, Mouse)	050-69	492.3
13	CAP-DEFA-RS7 (Mouse)	050-37	741.3
14	CAP-METTL24 (Mouse)	050-39	833.4
15	CAP-TENM1 (Mouse)	050-41	902.4
16	CAP-CA15 (Mouse)	050-79	395.2
17	CAP-ANGPTL4 (Mouse)	050-30	2074.2
18	GnRH (Human, Mouse)	040-02	1182
19	CAP-CNPY4/CAP-GDF18 Homolog (Mouse)	050-77	556.3
20	CAP-NTN4 (Mouse)	050-80	860.5
21	CAP-GDNF(Mouse)	050-72	1267.6
22	CAP-TAC4 (Mouse)	050-81	739.3
23	CAP-DEFB1 (Mouse)	050-82	1225.6
24	CAP-PRG4 (Mouse)	050-83	1002.5
25	CAP-PLA2G2A (Mouse)	050-84	1203.6
26	CAP-FGF18 (Human, Mouse)	050-66	340.2
27	CAP-LY86 (Mouse)	050-85	894.4
28	CAP-VIP-2 (Mouse)	064-12	1502.8
29	CAP-PRSS36 (Mouse)	050-86	1429.7
30	CAP-GNAS (Mouse)	050-87	2077
31	CAP-GDF15 (Mouse)	050-70	1362.8
32	CAP-TAC3 (Mouse)	050-88	1604.8
33	CAP-EGFL8 (Mouse)	050-89	1422.7
34	CAP-COL5A2-2 (Mouse)	050-60	1655.9
35	CAP-MST1 (Mouse)	050-91	890.4
36	CAP-ALKAL2 (Mouse)	050-92	1073.5
37	CAP-GDF6 (Mouse)	050-93	1320.7
38	CAP-GCG (Mouse)	050-94	1597.9
39	Gastrin (Human)	027-04	2098.2
40	CAP-GDF15 (Human)	050-71	1413.7
41	CAP-COL5A2 (Mouse)	050-54	353.2
42	CAP-Coagulation factor 5 (Human)	050-95	1901.0
43	CAP-EDN3 (Human)	050-96	1725.9
44	CAP-Q59F13 (Human)	050-97	761.4
45	CAP-GDNF (Human)	050-75	1295.4
46	CAP-VIP (Human)	064-12	1502.8
47	CAP-LOXL3 (Human)	050-98	1519.8
48	CAP-PRG4 (Human)	050-99	513.2
49	CAP-VEGFA (Human)	051-11	1507.7
50	CAP-CRLF1 (Human)	051-12	839.4
51	CAP-FURIN (Human)	051-13	1823.0
52	CAP-TG (Human)	051-14	936.5
53	CAP-MEGF6-2 (Human)	051-16	683.4
54	CAP-IFNG-1 (Human)	051-17	1226.6
55	CAP-SIGLEC1 (Human)	051-18	1685.8
56	CAP-CPAMD8-2 (Human)	051-23	665.3
57	CAP-CBLN2 (Human)	051-22	1574.9
58	CAP-CPAMD8-1 (Human)	051-19	1913.0
59	CAP-PMCH (Human)	051-24	1971.0
60	CAP-LEFTY2 (Human)	051-32	1823.0
61	CAP-OSM (Human)	051-33	1790.1
62	CAP-COL11A2 (Human)	050-62	1543.7
63	CAP-F8 (Human)	051-34	2108.0
64	CAP-MUC4 (Human)	051-35	796.4
65	CAP-BMP4 (Human)	051-36	450.2
66	CAP-COL4A4 (Human)	051-37	1568.8
67	CAP-LGALS9 (Human)	051-38	1234.6
68	CAP-LIPC (Human)	051-39	926.5
69	CAP-WNT9A (Human)	051-40	2344.1
70	CAP-VWF (Human)	051-41	1759.7
71	CAP-THSD1 (Human)	051-42	1571.9
72	CAP-GDF15 (Human)	050-71	1412.8
73	CAP-COL6A3 (Human)	051-43	832.4
74	CAP-COL11A1-1 (Human)	051-44	1476.7
75	CAP-PAPPA2 (Human)	051-45	1117.6
76	CAP-ADAMTS1 (Human)	051-46	884.5
77	TRH (Human)	062-10	362.4
78	CAP-MMP16 (Human)	051-47	2090.0
79	CAP-CILP2 (Human)	051-48	381.2
80	CAP-LGI3 (Human)	051-49	641.4
Plate II
81	CAP-NXPE4 (Human)	051-50	1466.8
82	pGlu(Lys8GluPAL)-apelin-13-amide	057-09	1900.5
83	Fractalkine (CX3CL1) Domain (1-34)(Human)	026-86	3765.4
84	Phoenixin-25 amide (Pig)	079-15	2748.1
85	GHRF(30-44)-amide	031-12	1681.8
86	Gastrin I (Mouse)	027-05	2185.0
87	Orexin B (8-28) amide (Human)	027-13	2217.6
88	Oxytocin metabolite neuropeptide	051-05	731.2
89	pGlu-Glu-Pro-NH2 /TRH-like	062-03	354.1
90	pGlu-Gln-Pro-NH2 /TRH-like	062-25	353.2
91	pGlu-His-Pro-Gly amide	062-06	419.4
92	pGlu-Phe-Pro-NH2 /TRH-like	062-11	372.4
93	pGlu-Asn-Pro-NH2 /TRH-like	062-12	339.4
94	pGlu-Tyr-Pro-NH2 /TRH-like	062-14	388.4
95	pGlu-Val-Pro-NH2 /TRH-like	062-15	324.4
96	pGlu-Leu-Pro-NH2 /TRH-like	062-16	338.4
97	Orexin A	003-30	3561.4
98	FMRF-Like Peptide	047-31	903.3
99	QRFP-43 (Human)	048-78	2103.3
100	CAP-CSF1 (Human)	050-74	2103.3
101	Myoactive Peptide II (M II) / Periplanetin CC-2	047-53	987.5
102	PG-KII (Pseudophryne guntheri)	046-44	1227.5
103	PG-KIII (Pseudophryne guntheri)	046-45	1249.6
104	Phyllolitorin (Phyllomedusa sauvagei)	046-46	1019.5
105	[Leu8]-Phyllolitorin (Phyllomedusa sauvagei)	046-47	985.5
106	Phyllomedusin	046-48	1170.6
107	Physalaemin	046-49	1264.6
108	Ranatensin	046-53	1280.6
109	Uperolein	046-69	1233.5

Screen hundreds of peptides at one time by choosing our peptide libraries

More Information

Updates coming soon

Our Cancer and Immunomodulatory Peptide Libraries allow for hundreds of cancer-related peptides to be analyzed in parallel. This can drastically reduce the time needed for your drug discovery, ligand-binding, or antibody development efforts.

The effects of programmed cell death 1 (PD-1)−programmed death 1/2 ligand (PD-L1/2) interaction on T cells. PD-L1/2 is expressed by tumor cells and antigen-presenting cells (APCs). In tumor cells, PD-L1 expression may be induced by interaction between IFN-γ and IFN-γ receptor (IFN-γ R), activation of epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), and/or PI3K-Akt signaling pathways, and upregulation of signal transducer and activator of transcription 3 (STAT3) or hypoxia induced factor 1 (HIF-1). Then, interaction of PD-1 with PD-L1 can activate Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) and inhibit activation of T cell receptor (TCR)/major histocompatibility complex (MHC)-triggered NF-κB, PI3K, or other signaling pathways, leading to increased apoptosis and impaired T cell function, migration, and proliferation.

Figure from: Song M et. Al. Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chin J Cancer Res. 2018 Apr; 30(2): 157–172. doi: 10.21147/j.issn.1000-9604.2018.02.01

T cell inhibitory receptor PD-1 expressed on tumor cells and tumor-infiltrating APCs neutralizes its ligand, PD-L1, in cis to inhibit canonical PD-1 signaling.

The interaction between PD-1 on T cells and its ligand PD-L1, which is highly expressed on several types of human tumor cells and tumor infiltrating immune cells, restrains the activity of effector T cells against human cancers and chronic virus infections.

Zhao et al. (Cell Rep. 2018 Jul 10;24(2):379-390) show that the T cell inhibitory receptor PD-1 expressed on tumor cells and tumor-infiltrating APCs neutralizes its ligand, PD-L1, in cis to inhibit canonical PD-1 signaling. Selective blockade of tumor-intrinsic PD-1 frees up tumor PDL1 for T cell suppression. Peptide/protein that block PD-L1/PD-1 interactions have produced durable clinical benefits.

No References

Social Network Confirmation

Account Activation